Ziprasidone Injection

Generic name: Pronounced as (zi pray' si done)
Brand names
  • Geodon®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 07/15/2017

Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who use antipsychotics (medications for mental illness) such as ziprasidone injection have an increased risk of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini stroke during treatment.

Ziprasidone injection is not approved by the Food and Drug Administration (FDA) for the treatment of behavior problems in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is receiving ziprasidone. For more information visit the FDA website: http://www.fda.gov/Drugs.

Talk to your doctor about the risks of receiving ziprasidone injection.

Ziprasidone injection is used to treat episodes of agitation in people who have schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Ziprasidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Ziprasidone injection come as a powder to be mixed with water and injected into a muscle by a healthcare provider. Ziprasidone injection is usually given as needed for agitation. If you are still agitated after you receive your first dose, you may be given one or more additional doses.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving ziprasidone injection,

  • tell your doctor and pharmacist if you are allergic to ziprasidone, any other medications, or any of the ingredients in ziprasidone injection. Ask your pharmacist for a list of the ingredients.

  • tell your doctor if you are taking amiodarone (Cordarone, Nexterone, Pacerone), arsenic trioxide (Trisenox), chlorpromazine, disopyramide (Norpace), dofetilide (Tikosyn), dolasetron (Anzemet), dronedarone (Multaq), droperidol (Inapsine), gatifloxacin (no longer available in the U.S.), ibutilide (Corvert), halofantrine (Halfan) (no longer available in the U.S.), levomethadyl (ORLAAM) (no longer available in the U.S.), mefloquine, mesoridazine (no longer available in the U.S.), moxifloxacin (Avelox), pentamidine (NebuPent, Pentam), pimozide (Orap), probucol (no longer available in the U.S.), procainamide, quinidine (in Nuedexta), sotalol (Betapace, Sorine, Sotylize), sparfloxacin (no longer available in the U.S.), tacrolimus (Astagraf, Prograf), or thioridazine. Your doctor may not prescribe ziprasidone if you are taking one or more of these medications. Other medications may also interact with ziprasidone, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antidepressants, carbamazepine (Carbatrol, Tegretol, Teril, others), certain antifungals such as ketoconazole (Extina, Nizoral), dopamine agonists such as bromocriptine (Cycloset, Parlodel), cabergoline, levodopa (in Sinemet), pergolide (Permax) (no longer available in the U.S.), and ropinirole (Requip), medications for high blood pressure, mental illness, seizures, or anxiety; and sedatives, sleeping pills, or tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have heart failure, QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), or if you have recently had a heart attack. Your doctor will probably tell you not to receive ziprasidone injection.

  • tell your doctor if you have or have had thoughts about harming or killing yourself, an irregular heartbeat, a stroke or ministroke, seizures, diabetes, dyslipidemia (high cholesterol levels), trouble keeping your balance, a low number of white blood cells, or heart, kidney, or liver disease. Also, tell your doctor if you low levels of potassium or magnesium in your blood, if you use or have ever used street drugs or have overused prescription medications, or have trouble swallowing. Also, tell your doctor if you have severe diarrhea or vomiting or you think you may be dehydrated.

  • ask your doctor about the safe use of alcoholic beverages while you are receiving ziprasidone injection. Alcohol can make the side effects from ziprasidone injection worse.

  • tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breastfeeding. If you become pregnant while receiving ziprasidone, call your doctor. Ziprasidone may cause problems in newborns following delivery if it is given during the last months of pregnancy.

  • you should know that ziprasidone injection may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • you should know that alcohol can add to the drowsiness caused by this medication. Do not drink alcohol while receiving ziprasidone.

  • you should know that you may experience hyperglycemia (increases in your blood sugar) while you are receiving this medication, even if you do not already have diabetes. If you have schizophrenia, you are more likely to develop diabetes than people who do not have schizophrenia, and receiving ziprasidone or similar medications may increase this risk. Tell your doctor immediately if you have any of the following symptoms while you are receiving ziprasidone: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms, because high blood sugar that is not treated can cause a serious condition called ketoacidosis. Ketoacidosis may become life-threatening if it is not treated at an early stage. Symptoms of ketoacidosis include dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, and decreased consciousness.

  • you should know that ziprasidone injection may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start receiving ziprasidone. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

  • you should know that ziprasidone injection may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to do vigorous exercise or be exposed to extreme heat.

  • Ziprasidone injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • headache

    • injection site pain

    • nausea

    • vomiting

    • restlessness

    • heartburn

    • anxiety

    • agitation

    • lack of energy

    • constipation

    • diarrhea

    • loss of appetite

    • weight gain

    • stomach pain

    • pricking, or tingling feeling

    • speech problems

    • breast enlargement or discharge

    • late or missed menstrual period

    • decreased sexual ability

    • dizziness, feeling unsteady, or having trouble keeping your balance

  • Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or the SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment:

    • unusual movements of your face or body that you cannot control

    • rash

    • hives

    • itching

    • blisters or peeling of skin

    • mouth sores

    • swollen glands

    • fever

    • chills

    • yellowing of the skin or eyes

    • shortness of breath

    • fast, irregular, or pounding heartbeat

    • shaking

    • muscle stiffness

    • falling

    • confusion

    • sweating

    • loss of consciousness

    • painful erection of the penis that lasts for hours

  • Ziprasidone injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • drowsiness

  • slurred speech

  • sudden movements that you cannot control

  • uncontrollable shaking of a part of the body

  • anxiety

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to ziprasidone injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ziprasidone.
Repaglinide Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Ziprasidone.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ziprasidone.
Delavirdine Delavirdine The metabolism of Ziprasidone can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Ziprasidone can be decreased when combined with Nevirapine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Ziprasidone.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ziprasidone.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Ziprasidone.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Ziprasidone.
Candesartan Candesartan Ziprasidone may increase the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Cilostazol.
Clopidogrel Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Ziprasidone.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ziprasidone.
Fenofibrate Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Ziprasidone.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Guanfacine.
Magnesium Hydroxide Magnesium Hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ziprasidone.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ziprasidone.
Methylergonovine Methylergonovine Methylergometrine may increase the vasoconstricting activities of Ziprasidone.
Miglitol Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Ziprasidone is combined with Naratriptan.
Olsalazine Olsalazine The risk or severity of hypertension can be increased when Ziprasidone is combined with Olsalazine.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Ziprasidone is combined with Morphine.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Ziprasidone.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ziprasidone.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Ziprasidone.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Ziprasidone is combined with Rizatriptan.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Ziprasidone is combined with Sumatriptan.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Tacrolimus.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ziprasidone.
Triamcinolone Triamcinolone The metabolism of Ziprasidone can be increased when combined with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of vasospastic reactions can be increased when Zolmitriptan is combined with Ziprasidone.
Doxycycline Injection Doxycycline Injection The metabolism of Ziprasidone can be decreased when combined with Doxycycline.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ziprasidone.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ziprasidone.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ziprasidone.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Hydromorphone.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ziprasidone.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meperidine.
Methylprednisolone Injection Methylprednisolone Injection The metabolism of Ziprasidone can be increased when combined with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Ziprasidone.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Morphine.
Altretamine Altretamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Ziprasidone.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ondansetron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ziprasidone.
Torsemide Torsemide Ziprasidone may increase the antihypertensive activities of Torasemide.
Olanzapine Olanzapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Olanzapine.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Ziprasidone.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Dofetilide.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone.
Eprosartan Eprosartan Ziprasidone may increase the antihypertensive activities of Eprosartan.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ziprasidone.
Meloxicam Meloxicam The risk or severity of hypertension can be increased when Ziprasidone is combined with Meloxicam.
Orlistat Orlistat The metabolism of Ziprasidone can be increased when combined with Orlistat.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Ziprasidone.
Telmisartan Telmisartan Ziprasidone may increase the antihypertensive activities of Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zaleplon.
Anakinra Anakinra The metabolism of Ziprasidone can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Ziprasidone.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Ziprasidone.
Rivastigmine Rivastigmine The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Ziprasidone.
Etanercept Injection Etanercept Injection The metabolism of Ziprasidone can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Glycopyrronium.
Modafinil Modafinil The metabolism of Ziprasidone can be increased when combined with Modafinil.
Perindopril Perindopril Perindopril may increase the antihypertensive activities of Ziprasidone.
Tenofovir Tenofovir The metabolism of Tenofovir can be decreased when combined with Ziprasidone.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of hypertension can be increased when Ziprasidone is combined with Choline magnesium trisalicylate.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Ziprasidone.
Dutasteride Dutasteride The metabolism of Dutasteride can be decreased when combined with Ziprasidone.
Epinephrine Injection Epinephrine Injection The therapeutic efficacy of Epinephrine can be decreased when used in combination with Ziprasidone.
Eplerenone Eplerenone The metabolism of Eplerenone can be decreased when combined with Ziprasidone.
Escitalopram Escitalopram The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Escitalopram.
Olmesartan Olmesartan Ziprasidone may increase the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Ziprasidone.
Adalimumab Injection Adalimumab Injection The metabolism of Ziprasidone can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ziprasidone.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Ziprasidone.
Almotriptan Almotriptan The risk or severity of adverse effects can be increased when Ziprasidone is combined with Almotriptan.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Ziprasidone is combined with Eletriptan.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Ziprasidone.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ziprasidone.
Rosuvastatin Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Ziprasidone.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Vardenafil.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Alfuzosin.
Aprepitant Aprepitant The metabolism of Ziprasidone can be decreased when combined with Aprepitant.
Memantine Memantine The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Memantine.
Tegaserod Tegaserod The risk or severity of serotonin syndrome can be increased when Ziprasidone is combined with Tegaserod.
Tadalafil Tadalafil Ziprasidone may increase the antihypertensive activities of Tadalafil.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Ziprasidone.
Progesterone Progesterone The metabolism of Progesterone can be increased when combined with Ziprasidone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ziprasidone.
Infliximab Injection Infliximab Injection The metabolism of Ziprasidone can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ziprasidone.
Rifaximin Rifaximin The metabolism of Ziprasidone can be increased when combined with Rifaximin.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Norethisterone can be decreased when combined with Ziprasidone.
Trospium Trospium Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan Bosentan may increase the antihypertensive activities of Ziprasidone.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Ziprasidone is combined with Eszopiclone.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ziprasidone.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Ziprasidone.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ziprasidone.
Dextroamphetamine Dextroamphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Ziprasidone.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Ziprasidone.
Sodium Oxybate Sodium Oxybate The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Ziprasidone.
Exenatide Injection Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Ziprasidone.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Ziprasidone is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ramelteon.
Darifenacin Darifenacin Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The metabolism of Fentanyl can be decreased when combined with Ziprasidone.
Pregabalin Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ziprasidone.
Deferasirox Deferasirox The metabolism of Ziprasidone can be increased when combined with Deferasirox.
Phenylephrine Phenylephrine The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Ziprasidone.
Tipranavir Tipranavir The metabolism of Ziprasidone can be decreased when combined with Tipranavir.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Ziprasidone.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ziprasidone.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Ziprasidone can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Imatinib.
Sitagliptin Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ziprasidone.
Gefitinib Gefitinib The metabolism of Ziprasidone can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ziprasidone.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ziprasidone.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ziprasidone.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ziprasidone.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Ziprasidone.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Ziprasidone.
Aliskiren Aliskiren Ziprasidone may increase the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate Ziprasidone may increase the neurotoxic activities of Bismuth subsalicylate.
Darunavir Darunavir The metabolism of Ziprasidone can be decreased when combined with Darunavir.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ziprasidone.
Lisdexamfetamine Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Ziprasidone.
Nabilone Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Ziprasidone.
Retapamulin Retapamulin The metabolism of Retapamulin can be decreased when combined with Ziprasidone.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Ziprasidone.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ziprasidone.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ziprasidone.
Dronabinol Dronabinol The risk or severity of adverse effects can be increased when Dronabinol is combined with Ziprasidone.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Ziprasidone.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ziprasidone.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Dasatinib.
Armodafinil Armodafinil The metabolism of Ziprasidone can be increased when combined with Armodafinil.
Ivermectin Ivermectin The metabolism of Ziprasidone can be increased when combined with Ivermectin.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Ziprasidone.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Ziprasidone.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Toremifene.
Bexarotene Bexarotene The metabolism of Ziprasidone can be increased when combined with Bexarotene.
Budesonide Budesonide The metabolism of Ziprasidone can be increased when combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Ziprasidone can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Ziprasidone.
Betaine Betaine The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum Toxin Type B.
Etravirine Etravirine The metabolism of Ziprasidone can be increased when combined with Etravirine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The metabolism of Ziprasidone can be decreased when combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Desvenlafaxine.
Nebivolol Nebivolol Nebivolol may increase the antihypertensive activities of Ziprasidone.
Tretinoin Tretinoin The metabolism of Tretinoin can be decreased when combined with Ziprasidone.
Pilocarpine Pilocarpine The metabolism of Ziprasidone can be decreased when combined with Pilocarpine.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Ziprasidone.
Certolizumab Injection Certolizumab Injection The metabolism of Ziprasidone can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The metabolism of Ixabepilone can be decreased when combined with Ziprasidone.
Irinotecan Injection Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Ziprasidone.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Ziprasidone.
Mitotane Mitotane The metabolism of Ziprasidone can be increased when combined with Mitotane.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone.
Silodosin Silodosin Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.
Midazolam Midazolam The serum concentration of Midazolam can be increased when it is combined with Ziprasidone.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Naltrexone.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Ziprasidone is combined with Milnacipran.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Ziprasidone.
Fesoterodine Fesoterodine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ziprasidone.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ziprasidone.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Iloperidone.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lacosamide.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Ziprasidone.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Ziprasidone.
Dronedarone Dronedarone Ziprasidone may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum toxin type A.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Palonosetron.
Saxagliptin Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ziprasidone.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Ziprasidone.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
Topotecan Topotecan The metabolism of Ziprasidone can be increased when combined with Topotecan.
Golimumab Injection Golimumab Injection The metabolism of Ziprasidone can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Ziprasidone.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Vigabatrin.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Ziprasidone.
Levonorgestrel Levonorgestrel The metabolism of Levonorgestrel can be decreased when combined with Ziprasidone.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxymorphone.
Liraglutide Injection Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ziprasidone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Ziprasidone can be increased when combined with Tocilizumab.
Fingolimod Fingolimod The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Ziprasidone.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ziprasidone.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum toxin type A.
Cabazitaxel Injection Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The metabolism of Ziprasidone can be increased when combined with Acetaminophen.
Vilazodone Vilazodone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Vilazodone.
Denileukin Diftitox Injection Denileukin Diftitox Injection The metabolism of Ziprasidone can be decreased when combined with Aldesleukin.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ziprasidone.
Busulfan Injection Busulfan Injection The metabolism of Busulfan can be decreased when combined with Ziprasidone.
Roflumilast Roflumilast The metabolism of Roflumilast can be decreased when combined with Ziprasidone.
Linagliptin Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Rilpivirine.
Telaprevir Telaprevir The metabolism of Ziprasidone can be decreased when combined with Glecaprevir.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Ziprasidone can be decreased when combined with Cyclophosphamide.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ziprasidone.
Rivaroxaban Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.
Ticagrelor Ticagrelor The metabolism of Ziprasidone can be decreased when combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The metabolism of Ziprasidone can be decreased when combined with Brentuximab vedotin.
Ruxolitinib Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Vandetanib.
Clobazam Clobazam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clobazam.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ziprasidone.
Ivacaftor Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Ziprasidone.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Ziprasidone.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Ziprasidone.
Cabergoline Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Ziprasidone.
Naloxone Injection Naloxone Injection The metabolism of Ziprasidone can be decreased when combined with Naloxone.
Ambrisentan Ambrisentan Ziprasidone may increase the antihypertensive activities of Ambrisentan.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiagabine.
Enzalutamide Enzalutamide The metabolism of Ziprasidone can be increased when combined with Enzalutamide.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Mirabegron.
Regorafenib Regorafenib The metabolism of Ziprasidone can be decreased when combined with Regorafenib.
Bosutinib Bosutinib The metabolism of Ziprasidone can be decreased when combined with Bosutinib.
Corticotropin, Repository Injection Corticotropin, Repository Injection The metabolism of Ziprasidone can be increased when combined with Corticotropin.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Ziprasidone.
Lorcaserin Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Ziprasidone.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Ziprasidone.
Tofacitinib Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Ziprasidone.
Alogliptin Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Ziprasidone.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The metabolism of Ziprasidone can be decreased when combined with Trastuzumab emtansine.
Apixaban Apixaban The metabolism of Apixaban can be decreased when combined with Ziprasidone.
Canagliflozin Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ziprasidone.
Trametinib Trametinib The metabolism of Ziprasidone can be increased when combined with Trametinib.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levomilnacipran.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Vortioxetine.
Perampanel Perampanel The risk or severity of adverse effects can be increased when Perampanel is combined with Ziprasidone.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Ziprasidone.
Lomitapide Lomitapide The metabolism of Lomitapide can be decreased when combined with Ziprasidone.
Avanafil Avanafil The metabolism of Avanafil can be decreased when combined with Ziprasidone.
Ketorolac Injection Ketorolac Injection The risk or severity of hypertension can be increased when Ziprasidone is combined with Ketorolac.
Simeprevir Simeprevir The metabolism of Ziprasidone can be decreased when combined with Simeprevir.
Dapagliflozin Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ziprasidone.
Apremilast Apremilast The metabolism of Ziprasidone can be increased when combined with Apremilast.
Droxidopa Droxidopa Ziprasidone may increase the hypertensive activities of Droxidopa.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Ziprasidone.
Siltuximab Injection Siltuximab Injection The metabolism of Ziprasidone can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ziprasidone.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Eslicarbazepine.
Idelalisib Idelalisib The metabolism of Idelalisib can be decreased when combined with Ziprasidone.
Testosterone Injection Testosterone Injection The metabolism of Ziprasidone can be increased when combined with Testosterone.
Oritavancin Injection Oritavancin Injection The metabolism of Ziprasidone can be increased when combined with Oritavancin.
Empagliflozin Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.
Vorapaxar Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Ziprasidone.
Hydrocodone Hydrocodone Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Ziprasidone.
Methamphetamine Methamphetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Ziprasidone.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tasimelteon.
Riociguat Riociguat Ziprasidone may increase the antihypertensive activities of Riociguat.
Lanreotide Injection Lanreotide Injection The metabolism of Ziprasidone can be decreased when combined with Lanreotide.
Nintedanib Nintedanib The metabolism of Nintedanib can be decreased when combined with Ziprasidone.
Secukinumab Injection Secukinumab Injection The metabolism of Ziprasidone can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Risperidone.
Palbociclib Palbociclib The metabolism of Ziprasidone can be decreased when combined with Palbociclib.
Insulin Human Inhalation Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Ziprasidone.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ziprasidone.
Naloxegol Naloxegol The metabolism of Naloxegol can be decreased when combined with Ziprasidone.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Ziprasidone.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Haloperidol.
Ivabradine Ivabradine The metabolism of Ivabradine can be decreased when combined with Ziprasidone.
Isavuconazonium Injection Isavuconazonium Injection The metabolism of Ziprasidone can be increased when combined with Isavuconazonium.
Macitentan Macitentan Ziprasidone may increase the antihypertensive activities of Macitentan.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Ziprasidone.
Flibanserin Flibanserin The metabolism of Flibanserin can be decreased when combined with Ziprasidone.
Prednisolone Prednisolone The metabolism of Ziprasidone can be increased when combined with Prednisolone.
Daclatasvir Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Ziprasidone.
Brexpiprazole Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Ziprasidone.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cariprazine.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Ziprasidone is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ziprasidone.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Ziprasidone.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Ziprasidone.
Osimertinib Osimertinib The metabolism of Osimertinib can be decreased when combined with Ziprasidone.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Ziprasidone.
Ixazomib Ixazomib The metabolism of Ixazomib can be decreased when combined with Ziprasidone.
Rifapentine Rifapentine The metabolism of Ziprasidone can be increased when combined with Rifapentine.
Lesinurad Lesinurad The metabolism of Ziprasidone can be increased when combined with Lesinurad.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The metabolism of Ziprasidone can be decreased when combined with Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The metabolism of Ziprasidone can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Brivaracetam.
Venetoclax Venetoclax The metabolism of Venetoclax can be decreased when combined with Ziprasidone.
Cobicistat Cobicistat The metabolism of Ziprasidone can be decreased when combined with Cobicistat.
Midodrine Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Ziprasidone.
Selexipag Selexipag Ziprasidone may increase the antihypertensive activities of Selexipag.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ziprasidone.
Furosemide Injection Furosemide Injection Ziprasidone may increase the antihypertensive activities of Furosemide.
Rucaparib Rucaparib The metabolism of Ziprasidone can be decreased when combined with Rucaparib.
Lixisenatide Injection Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ziprasidone.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ribociclib.
Brigatinib Brigatinib The metabolism of Ziprasidone can be decreased when combined with Brigatinib.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Doxepin.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Ziprasidone.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Deutetrabenazine.
Valbenazine Valbenazine The metabolism of Valbenazine can be decreased when combined with Ziprasidone.
Deflazacort Deflazacort The serum concentration of Ziprasidone can be increased when it is combined with Deflazacort.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Safinamide is combined with Ziprasidone.
Sarilumab Injection Sarilumab Injection The metabolism of Ziprasidone can be increased when combined with Sarilumab.
Midostaurin Midostaurin The metabolism of Ziprasidone can be decreased when combined with Midostaurin.
Neratinib Neratinib The metabolism of Neratinib can be decreased when combined with Ziprasidone.
Enasidenib Enasidenib The metabolism of Ziprasidone can be decreased when combined with Enasidenib.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The metabolism of Ziprasidone can be increased when combined with Fosaprepitant.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Ziprasidone.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ziprasidone.
Abemaciclib Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Ziprasidone.
Acalabrutinib Acalabrutinib The metabolism of Ziprasidone can be decreased when combined with Acalabrutinib.
Letermovir Letermovir The metabolism of Ziprasidone can be decreased when combined with Letermovir.
Semaglutide Injection Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ziprasidone.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Ziprasidone.
Buprenorphine Injection Buprenorphine Injection Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The metabolism of Ziprasidone can be increased when combined with Apalutamide.
Fostamatinib Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Ziprasidone.
Baricitinib Baricitinib The metabolism of Baricitinib can be decreased when combined with Ziprasidone.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Ziprasidone.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Ziprasidone.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Ziprasidone.
Doravirine Doravirine The metabolism of Doravirine can be decreased when combined with Ziprasidone.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ziprasidone.
Dacomitinib Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Ziprasidone.
Duvelisib Duvelisib The metabolism of Duvelisib can be decreased when combined with Ziprasidone.
Stiripentol Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Ziprasidone.
Gilteritinib Gilteritinib The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Ziprasidone.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Ziprasidone.
Rifamycin Rifamycin The metabolism of Ziprasidone can be increased when combined with Rifamycin.
Prucalopride Prucalopride The metabolism of Prucalopride can be decreased when combined with Ziprasidone.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Ziprasidone.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Ziprasidone can be increased when combined with Emapalumab.
Siponimod Siponimod The risk or severity of adverse effects can be increased when Ziprasidone is combined with Siponimod.
Erdafitinib Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Ziprasidone.
Alpelisib Alpelisib The metabolism of Alpelisib can be decreased when combined with Ziprasidone.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Ziprasidone.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Ziprasidone.
Entrectinib Entrectinib The metabolism of Entrectinib can be decreased when combined with Ziprasidone.
Pexidartinib Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Ziprasidone.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Ziprasidone.
Pitolisant Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Ziprasidone.
Pretomanid Pretomanid The serum concentration of Pretomanid can be increased when it is combined with Ziprasidone.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Ziprasidone.
Phenytoin Injection Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Ziprasidone.
Fosphenytoin Injection Fosphenytoin Injection The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ziprasidone.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Ziprasidone.
Voxelotor Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Ziprasidone.
Lumateperone Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Ziprasidone.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Ziprasidone is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Ziprasidone.
Tazemetostat Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Ziprasidone.
Cenobamate Cenobamate The serum concentration of Ziprasidone can be decreased when it is combined with Cenobamate.
Pemigatinib Pemigatinib The metabolism of Pemigatinib can be decreased when combined with Ziprasidone.
Selumetinib Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Ziprasidone.
Rimegepant Rimegepant The metabolism of Rimegepant can be decreased when combined with Ziprasidone.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Ziprasidone.
Selpercatinib Selpercatinib The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Selpercatinib.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lemborexant.
Daratumumab and Hyaluronidase-fihj Injection Daratumumab and Hyaluronidase-fihj Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ziprasidone.
Fenfluramine Fenfluramine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fenfluramine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Ziprasidone.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ziprasidone.
Lurbinectedin Injection Lurbinectedin Injection The serum concentration of Lurbinectedin can be increased when it is combined with Ziprasidone.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ziprasidone.
Pralsetinib Pralsetinib The metabolism of Ziprasidone can be increased when combined with Pralsetinib.
Opicapone Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Ziprasidone.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Ziprasidone can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Ziprasidone is combined with Naxitamab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Ziprasidone.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Ziprasidone can be decreased when combined with Drospirenone.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Viloxazine.
Vitamin E (Alpha-Tocopherol) Vitamin E (Alpha-Tocopherol) The metabolism of Ziprasidone can be increased when combined with Vitamin E.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Ziprasidone.
Fenoprofen Fenoprofen The risk or severity of hypertension can be increased when Ziprasidone is combined with Fenoprofen.
Indomethacin Indomethacin The risk or severity of hypertension can be increased when Ziprasidone is combined with Indomethacin.
Mefenamic Acid Mefenamic Acid The risk or severity of hypertension can be increased when Ziprasidone is combined with Mefenamic acid.
Naproxen Naproxen The risk or severity of hypertension can be increased when Ziprasidone is combined with Naproxen.
Tolmetin Tolmetin The risk or severity of hypertension can be increased when Ziprasidone is combined with Tolmetin.
Sulindac Sulindac The risk or severity of hypertension can be increased when Ziprasidone is combined with Sulindac.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ziprasidone.
Phenobarbital Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Ziprasidone.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.
Methotrexate Injection Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Ziprasidone.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol.
Primidone Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Ziprasidone.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ziprasidone.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Ziprasidone.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Diazepam.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Flurazepam.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clorazepic acid.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.
Phenoxybenzamine Phenoxybenzamine Ziprasidone may increase the antihypertensive activities of Phenoxybenzamine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ziprasidone.
Codeine Codeine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlordiazepoxide.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Bromocriptine.
Metaproterenol Metaproterenol The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Ziprasidone.
Tranylcypromine Tranylcypromine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tranylcypromine.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenelzine.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziprasidone.
Tetracycline Tetracycline The metabolism of Ziprasidone can be decreased when combined with Tetracycline.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluoperazine.
Dapsone Dapsone The metabolism of Dapsone can be decreased when combined with Ziprasidone.
Sulfadiazine Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ziprasidone.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ziprasidone.
Oxybutynin Oxybutynin The metabolism of Ziprasidone can be decreased when combined with Oxybutynin.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Maprotiline.
Ibuprofen Ibuprofen The risk or severity of hypertension can be increased when Ziprasidone is combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Ziprasidone.
Orphenadrine Orphenadrine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Perphenazine.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluphenazine.
Phentermine Phentermine Phentermine may decrease the sedative and stimulatory activities of Ziprasidone.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
Amoxapine Amoxapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of hypertension can be increased when Ziprasidone is combined with Sulfasalazine.
Hydrocortisone Hydrocortisone The metabolism of Ziprasidone can be increased when combined with Hydrocortisone.
Doxorubicin Doxorubicin The metabolism of Ziprasidone can be decreased when combined with Doxorubicin.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Pyridostigmine.
Carbamazepine Carbamazepine The serum concentration of Carbamazepine can be decreased when it is combined with Ziprasidone.
Molindone Molindone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone.
Methyldopa Methyldopa Ziprasidone may increase the antihypertensive activities of Methyldopa.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Ziprasidone.
Prazosin Prazosin Ziprasidone may increase the antihypertensive activities of Prazosin.
Hydralazine Hydralazine Hydralazine may increase the antihypertensive activities of Ziprasidone.
Cimetidine Cimetidine The metabolism of Ziprasidone can be decreased when combined with Cimetidine.
Warfarin Warfarin The serum concentration of Warfarin can be increased when it is combined with Ziprasidone.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clonazepam.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Ziprasidone.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ziprasidone.
Meclofenamate Meclofenamate The risk or severity of hypertension can be increased when Ziprasidone is combined with Meclofenamic acid.
Daunorubicin Daunorubicin The metabolism of Ziprasidone can be decreased when combined with Daunorubicin.
Griseofulvin Griseofulvin The metabolism of Ziprasidone can be increased when combined with Griseofulvin.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ziprasidone.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Ziprasidone.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Ethosuximide.
Calcitriol Calcitriol The metabolism of Ziprasidone can be increased when combined with Calcitriol.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Ziprasidone.
Sulfinpyrazone Sulfinpyrazone The metabolism of Ziprasidone can be increased when combined with Sulfinpyrazone.
Chlorothiazide Chlorothiazide Ziprasidone may increase the antihypertensive activities of Chlorothiazide.
Chlorthalidone Chlorthalidone Ziprasidone may increase the antihypertensive activities of Chlorthalidone.
Metolazone Metolazone Ziprasidone may increase the antihypertensive activities of Metolazone.
Clindamycin Injection Clindamycin Injection The metabolism of Clindamycin can be decreased when combined with Ziprasidone.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.
Desipramine Desipramine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Desipramine.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Amitriptyline.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Imipramine.
Probenecid Probenecid The metabolism of Ziprasidone can be increased when combined with Probenecid.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ziprasidone.
Isoniazid Isoniazid The metabolism of Ziprasidone can be decreased when combined with Isoniazid.
Rifampin Rifampin The metabolism of Rifampicin can be increased when combined with Ziprasidone.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ziprasidone.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone.
Methimazole Methimazole The metabolism of Ziprasidone can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.
Glucagon Injection Glucagon Injection Ziprasidone may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.
Tolazamide Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromethorphan.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Ziprasidone is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Ziprasidone can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Ziprasidone.
Doxylamine Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ziprasidone.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ziprasidone.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Ziprasidone.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ziprasidone.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meclizine.
Methyclothiazide Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Ziprasidone.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Ziprasidone.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorzoxazone.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziprasidone.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.
Danazol Danazol The metabolism of Ziprasidone can be decreased when combined with Danazol.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Ziprasidone.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Propranolol is combined with Ziprasidone.
Minoxidil Minoxidil Ziprasidone may increase the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Ziprasidone.
Nortriptyline Nortriptyline The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Nortriptyline.
Amphotericin B Injection Amphotericin B Injection The metabolism of Ziprasidone can be decreased when combined with Amphotericin B.
Nadolol Nadolol Nadolol may increase the antihypertensive activities of Ziprasidone.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ziprasidone.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trimethobenzamide.
Flavoxate Flavoxate Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ziprasidone.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ziprasidone.
Colchicine Colchicine The metabolism of Colchicine can be decreased when combined with Ziprasidone.
Cephalexin Cephalexin The metabolism of Cephalexin can be decreased when combined with Ziprasidone.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Ziprasidone is combined with Acetazolamide.
Ketoconazole Ketoconazole The serum concentration of Ziprasidone can be increased when it is combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pyrantel.
Thiotepa Injection Thiotepa Injection The metabolism of Ziprasidone can be decreased when combined with Thiotepa.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Ziprasidone.
Captopril Captopril Ziprasidone may increase the antihypertensive activities of Captopril.
Dipyridamole Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Ziprasidone.
Isoxsuprine Isoxsuprine The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Ziprasidone.
Vinblastine Vinblastine The metabolism of Ziprasidone can be decreased when combined with Vinblastine.
Metoprolol Metoprolol Metoprolol may increase the antihypertensive activities of Ziprasidone.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ziprasidone.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Thiothixene.
Aspirin Aspirin The risk or severity of hypertension can be increased when Ziprasidone is combined with Acetylsalicylic acid.
Salsalate Salsalate The risk or severity of hypertension can be increased when Ziprasidone is combined with Salsalate.
Alprazolam Alprazolam The metabolism of Alprazolam can be decreased when combined with Ziprasidone.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Ziprasidone.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Triazolam.
Dicyclomine Dicyclomine Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ziprasidone.
Propantheline Propantheline Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Ziprasidone.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Ziprasidone.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Timolol.
Verapamil Verapamil Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.
Atenolol Atenolol Atenolol may increase the antihypertensive activities of Ziprasidone.
Pindolol Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Ziprasidone.
Cisplatin Injection Cisplatin Injection The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Cisplatin.
Diflunisal Diflunisal The risk or severity of hypertension can be increased when Ziprasidone is combined with Diflunisal.
Piroxicam Piroxicam The risk or severity of hypertension can be increased when Ziprasidone is combined with Piroxicam.
Etoposide Etoposide The metabolism of Etoposide can be decreased when combined with Ziprasidone.
Glyburide Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Ziprasidone.
Glipizide Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Ziprasidone.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ziprasidone.
Dicloxacillin Dicloxacillin The metabolism of Ziprasidone can be increased when combined with Dicloxacillin.
Nafcillin Injection Nafcillin Injection The metabolism of Ziprasidone can be increased when combined with Nafcillin.
Pentoxifylline Pentoxifylline The risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Ziprasidone.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Ziprasidone.
Labetalol Labetalol Ziprasidone may increase the antihypertensive activities of Labetalol.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ziprasidone.
Guanabenz Guanabenz Ziprasidone may increase the antihypertensive activities of Guanabenz.
Ketoprofen Ketoprofen The risk or severity of hypertension can be increased when Ziprasidone is combined with Ketoprofen.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Pimozide.
Enalapril Enalapril Ziprasidone may increase the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen The risk or severity of hypertension can be increased when Ziprasidone is combined with Flurbiprofen.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Amiodarone.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Ziprasidone is combined with Buspirone.
Lovastatin Lovastatin The metabolism of Lovastatin can be decreased when combined with Ziprasidone.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ziprasidone.
Mesalamine Mesalamine The risk or severity of hypertension can be increased when Mesalazine is combined with Ziprasidone.
Diclofenac Diclofenac The risk or severity of hypertension can be increased when Ziprasidone is combined with Diclofenac.
Fluoxetine Fluoxetine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Ziprasidone.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Ziprasidone is combined with Estazolam.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Ziprasidone.
Didanosine Didanosine Ziprasidone may increase the neurotoxic activities of Didanosine.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Ziprasidone.
Benazepril Benazepril Ziprasidone may increase the antihypertensive activities of Benazepril.
Etodolac Etodolac The risk or severity of hypertension can be increased when Ziprasidone is combined with Etodolac.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Felodipine.
Fosinopril Fosinopril Ziprasidone may increase the antihypertensive activities of Fosinopril.
Nabumetone Nabumetone The risk or severity of hypertension can be increased when Ziprasidone is combined with Nabumetone.
Quinapril Quinapril Ziprasidone may increase the antihypertensive activities of Quinapril.
Ramipril Ramipril Ramipril may increase the antihypertensive activities of Ziprasidone.
Simvastatin Simvastatin The metabolism of Simvastatin can be decreased when combined with Ziprasidone.
Amlodipine Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Ziprasidone.
Teniposide Injection Teniposide Injection The metabolism of Ziprasidone can be decreased when combined with Teniposide.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Ziprasidone.
Lisinopril Lisinopril Ziprasidone may increase the antihypertensive activities of Lisinopril.
Oxaprozin Oxaprozin The risk or severity of hypertension can be increased when Ziprasidone is combined with Oxaprozin.
Rifabutin Rifabutin The metabolism of Ziprasidone can be increased when combined with Rifabutin.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ziprasidone.
Bisoprolol Bisoprolol Ziprasidone may increase the antihypertensive activities of Bisoprolol.
Zolpidem Zolpidem Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin Ziprasidone may increase the antihypertensive activities of Doxazosin.
Terazosin Terazosin Ziprasidone may increase the antihypertensive activities of Terazosin.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Ziprasidone.
Omeprazole Omeprazole The metabolism of Ziprasidone can be decreased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Ziprasidone can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Venlafaxine.
Nizatidine Nizatidine The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Nizatidine.
Stavudine Stavudine Ziprasidone may increase the neurotoxic activities of Stavudine.
Famciclovir Famciclovir The metabolism of Famciclovir can be decreased when combined with Ziprasidone.
Fluvoxamine Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ziprasidone.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lamotrigine.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Ziprasidone.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ziprasidone.
Vinorelbine Injection Vinorelbine Injection The metabolism of Vinorelbine can be decreased when combined with Ziprasidone.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ziprasidone.
Lansoprazole Lansoprazole The metabolism of Ziprasidone can be increased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The metabolism of Ziprasidone can be decreased when combined with Ifosfamide.
Nicardipine Nicardipine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Nicardipine.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Ziprasidone is combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Ziprasidone.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Saquinavir.
Metformin Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.
Nisoldipine Nisoldipine Ziprasidone may increase the antihypertensive activities of Nisoldipine.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Ziprasidone is combined with Riluzole.
Acarbose Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Ziprasidone.
Glimepiride Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.
Indinavir Indinavir The metabolism of Ziprasidone can be decreased when combined with Indinavir.
Ritonavir Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ziprasidone.
Docetaxel Injection Docetaxel Injection The metabolism of Ziprasidone can be decreased when combined with Docetaxel.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Ziprasidone.
Mirtazapine Mirtazapine Ziprasidone may increase the serotonergic activities of Mirtazapine.
Trandolapril Trandolapril Ziprasidone may increase the antihypertensive activities of Trandolapril.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Ziprasidone is combined with Topiramate.
Valsartan Valsartan Ziprasidone may increase the antihypertensive activities of Valsartan.
Insulin Lispro Injection Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ziprasidone.
Pramipexole Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Ziprasidone.
Donepezil Donepezil The risk or severity of QTc prolongation can be increased when Donepezil is combined with Ziprasidone.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ziprasidone.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Ziprasidone.
Loratadine Loratadine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Loratadine.
Carvedilol Carvedilol Ziprasidone may increase the antihypertensive activities of Carvedilol.
Flutamide Flutamide The metabolism of Flutamide can be decreased when combined with Ziprasidone.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Ziprasidone is combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Ziprasidone can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Sertraline.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Ziprasidone.
Raloxifene Raloxifene The metabolism of Ziprasidone can be decreased when combined with Raloxifene.
Irbesartan Irbesartan Irbesartan may increase the antihypertensive activities of Ziprasidone.
Tamsulosin Tamsulosin Ziprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tamsulosin.
Ropinirole Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Ziprasidone.
Finasteride Finasteride The metabolism of Finasteride can be decreased when combined with Ziprasidone.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ziprasidone.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ziprasidone.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Ziprasidone.
Sildenafil Sildenafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Sildenafil is combined with Ziprasidone.
Pioglitazone Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ziprasidone.
Celecoxib Celecoxib The risk or severity of hypertension can be increased when Ziprasidone is combined with Celecoxib.
Rosiglitazone Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Ziprasidone.
Thalidomide Thalidomide Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide The risk or severity of hypertension can be increased when Ziprasidone is combined with Balsalazide.
Nateglinide Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Ziprasidone.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ziprasidone.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziprasidone.
Rabeprazole Rabeprazole The metabolism of Ziprasidone can be decreased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Ziprasidone can be increased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists